Cotrimstada Forte Stada treatment for infection (10 blisters x 10 tablets)

Prostatitis.

Respiratory infections: Treatment of acute attacks of chronic bronchitis.

Gastrointestinal infections:

Treatment of acute otitis media.

Treatment of cholera when contraindicated with tetracycline or when infected with Vibrio Cholerae has resisted tetracyclin.

Treatment of pneumocystis jiroyeci pneumonia (Pneumocystis carinii before).

Prevention of toxoplasma disease, nocardia disease treatment.

Pharmacokological

cote Forte Stada 960mg (Co - Trimoxazol) is a form of coordination combination including sulfamethoxazol (5 parts) and trimethoprim (1 part), both are antibacterial antibacterial substances with folat synthesis. CO - trimoxazole acts by continuously inhibiting enzymes of folic acid metabolism; Sulfamethoxazol inhibits the formation of dihydrofolic acid from P - Aminobenzoic acid and trimethoprim inhibiting the formation of tetrahydrofolic acid from dihydrofolic acid by inhibiting dihydrofolate reductase. By inhibiting the synthesis of tetrahydrofolic acid is the active metabolic form of folic acid, co -trimoxazol inhibits the synthesis of bacterial thymidine.

The inhibition of two consecutive stages of Co - Trimoxazol is due to the antibacterial mechanism of the coordination of trimethoprim - sulfamethoxazol.

Effective against sensitive microorganisms of CO - trimoxazol is seen in trimethoprim than sulfamethoxazol. Co - Trimoxazol shows antibacterial antibacterial properties for many resistance bacteria sulfamethoxazol but sensitive or only sensitive to trimethoprim.

pharmacokinetic pharmacokinetics

co - trimoxazol absorbs well and quickly through the gastrointestinal tract. After taking the single doses of CO - Trimoxazol including 160mg Trimethoprim and 800mg Sulfamethoxazol, the peak concentration reached after 1-4 hours in the serum of Trimethoprim is 1 - 2mcg/ml and sulfamethoxazol united is 40 - 60mcg/ml.

Co - trimoxazol widely distributed in tissue and body fluid including saliva, aquatic fluid, middle ear fluid, prostate fluid, vaginal fluid, bile and cerebrospinal fluid; Trimethoprim is also distributed in lung secretion. The distribution volume of trimethoprim is higher than sulfamethoxazol. Trimethoprim binds with plasma proteins about 44% and sulfamethoxazol binds about 70%. CO - Trimoxazol easily through the placenta and distributed into breast milk.

Co - trimoxazol is metabolized through the liver. Trimethoprim's waste time is about 8 - 11 hours and sulfamethoxazol 10 - 13 hours in adults with normal kidney function. About 50 - 60% trimethoprim and 45 - 70% sulfamethoxazole oral dose are excreted through urine within 24 hours. About 80% trimethoprim and 20% sulfamethoxazole are found in urine in constant form. Only a small amount of trimethoprim is eliminated by stool due to secretion in the bile.

Prostatitis: 1 tablet every 12 hours in 3 - 6 months.

Respiratory infections:

Gastrointestinal infections:

Pregnant and lactating women.

Caution when using

Co - Trimoxazol should be careful with patients with renal impairment, patients with folat deficiency (such as elderly people, alcoholics, people who are taking anti -seizures, malnutrition people, people with poor absorbent syndrome), patients with severe allergens or bronchial asthma, or with patients with glucose deficiency (G-6-PD).

Patients who are taking co - trimoxazol should pay attention to maintain adequate drinking to avoid crystallizing urine and urolhyte formation.

Should regularly conduct blood formula tests, urine analysis, kidney function for patients being treated for a long time with Co - Trimoxazol.

Elderly people may be highly sensitive to the side effects of the drug.

The ability to drive and operate machinery

Co - Trimoxazol can cause dizziness, drowsiness, tinnitus, insomnia and hallucinations, patients should certainly not be affected before driving or operating machinery.

Pregnancy and lactation

Pregnancy

CO - trimoxazol passes through the placenta and can affect the metabolism of folic acid, so the drug is only used during pregnancy when the benefits of treatment are higher than the risk of harm to the fetus. Because sulfonamid can cause jaundice in infants, Co - Trimoxazol should be contraindicated for pregnant women.

Breastfeeding period

CO - Trimoxazol is distributed into breast milk. Because sulfonamid can cause jaundice in children under 2 months of age, decision to stop breastfeeding or stop using CO - trimoxazol or use other drugs instead, consider the importance of CO - trimoxazol for the mother.

Medicinal interaction

Warfarin: Co - Trimoxazol can extend the blood coagulation time of patients taking warfarin due to the drug inhibitance of the metabolic waste of warfarin.

Phenytoin: Co - trimoxazol inhibits the metabolism of phenytoin.

methotrexate: Because sulfonamid can occupy methotrexate in cohesion with plasma proteins thus increases the concentration of free methotrexate.

cyclosporin: signs of kidney poison but can recover in patients with kidney implants using CO - trimoxazol along with cyclosporin.

Digoxin: Increasing serum Digoxin levels can occur in patients using CO - Trimoxazol; This interaction often happens in the elderly.

indomethacin: Increased sulfamethoxazol levels in plasma can occur when patients are using indomethacin.

pyrimethamine: Large red blood cell anemia has been reported in patients using CO - trimoxazol and pyrimethamine more than 25mg/week (to prevent malaria).

Antidepressants: Co - Trimoxazol can reduce the effectiveness of 3 -round antidepressants.

Amantadin: Saturday poisoning has been reported when used in combination with co - trimoxazol with amantadin.